Immunovant (NASDAQ:IMVT) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Immunovant (NASDAQ:IMVT) released its earnings results on Wednesday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13), FiscalAI reports. During the same quarter last year, the business posted ($0.64) EPS.

Here are the key takeaways from Immunovant’s conference call:

• Roivant reported strong preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with roughly 73% ACR20, more than half achieving ACR50, and over a third reaching ACR70. Management emphasized that responses were seen in a heavily refractory population, including many patients who had failed both JAK inhibitors and TNFs.
• The company said IMVT-1402 was safe and well tolerated in the study, with no new drug-related safety signals identified. Management also said across hundreds of patients dosed to date, they have seen no impact on albumin or LDL.
• Roivant noted that the RA study’s period 2 randomized withdrawal portion is still ongoing, and management plans to use additional patient-level analysis plus FDA feedback to determine the path forward. They suggested the strong period 1 data could support a potentially lean registrational strategy.
• The company highlighted encouraging progress for mosociguat in PH-ILD, including phase I data showing deep pulmonary vascular resistance reductions and good tolerability without meaningful systemic side effects. In the phase II FOCUS study, Roivant said enrollment is complete and 95%+ of patients reached the 4 mg dose, with top-line data expected in the second half of 2026.
• Roivant reiterated a strong broader pipeline outlook, including expected repotrectinib launch in dermatomyositis by the end of September, ongoing development in cutaneous sarcoidosis and nail lichen planus, and continued enrollment in Graves’ disease and other FcRn programs. The company also ended the quarter with $4.3 billion in cash and equivalents before the Moderna settlement payment.

Immunovant Price Performance

IMVT opened at $34.13 on Friday. Immunovant has a fifty-two week low of $13.79 and a fifty-two week high of $36.28. The firm has a market capitalization of $6.95 billion, a PE ratio of -12.28 and a beta of 0.70. The company’s 50-day moving average is $26.65 and its 200 day moving average is $25.85.

Insiders Place Their Bets

In other Immunovant news, CFO Tiago Girao sold 25,760 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total value of $763,011.20. Following the completion of the sale, the chief financial officer directly owned 247,596 shares of the company’s stock, valued at approximately $7,333,793.52. This represents a 9.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Melanie Gloria sold 8,722 shares of the company’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $24.83, for a total transaction of $216,567.26. Following the completion of the sale, the chief operating officer directly owned 245,222 shares of the company’s stock, valued at $6,088,862.26. The trade was a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 78,141 shares of company stock worth $2,115,713 in the last ninety days. 1.80% of the stock is owned by corporate insiders.

Institutional Trading of Immunovant

Institutional investors have recently modified their holdings of the business. Strs Ohio purchased a new stake in Immunovant in the 1st quarter worth approximately $27,000. PNC Financial Services Group Inc. boosted its holdings in Immunovant by 138.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock valued at $46,000 after purchasing an additional 1,646 shares during the period. Quarry LP boosted its holdings in Immunovant by 94.9% in the 4th quarter. Quarry LP now owns 3,000 shares of the company’s stock valued at $76,000 after purchasing an additional 1,461 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Immunovant by 228.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,140 shares of the company’s stock valued at $98,000 after purchasing an additional 4,273 shares during the period. Finally, Royal Bank of Canada boosted its holdings in Immunovant by 20.7% in the 4th quarter. Royal Bank of Canada now owns 4,549 shares of the company’s stock valued at $116,000 after purchasing an additional 780 shares during the period. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Bank of America boosted their target price on shares of Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a report on Thursday. Citigroup reiterated a “buy” rating on shares of Immunovant in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunovant in a report on Wednesday, April 8th. HC Wainwright upped their price objective on shares of Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Finally, The Goldman Sachs Group upped their price objective on shares of Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $34.44.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.